Open-access in Research to Solve the Problems of Drug Industry

Rate this post

In the drug industry some of the leading names are experimenting with new ways to pool the research of the initial stage in order to make an attempt to save time and money. If this approach is able to take off successfully then it will definitely break the structure of current drug research and speed up the development of drugs which will be life saving in future. GlaxoSmithKline and Novartis were the first to sign up for the first phase of the new concept. On Wednesday at the University of Oxford Pfizer and Eli Lily also joined the existing backers. This happened in a very unusual public as well as private research partnership. The rivals as supporters of international Structural Genomics Consortium (SGC), provide cash and scientific resources for work into the structure of protein which is a three dimensional structure. This structure is very important for discovery of new drugs. The SGC has till date secured $49 million. A new scheme has been lined up for the next year. This new scheme will promote even higher level of cooperation and will promote open-access, research which is patent free till the stage of clinical trials.

This new bold idea requires the drug makers to trade exclusivity for a chance to get into the initial phase of the new therapies. Once the initial phase of sharing is over, the companies can redeem by developing their own version of the new medicines.
Drug industry

Since long patents have been considered to be the life and blood of the drug industry but today a large number of rebels believe that the current system which is building walls around the science is hampering the development. It proves to counter-productive because in the end companies are found to be working in parallel and duplicate research. Chas Bountra, the SGC’s chief scientist and a founder of the new project to take open-access research into the clinical arena said “It’s a horrendous waste of money, a horrendous waste of resource and waste of peoples’ careers. There is also an ethical and moral dilemma here because the way we are currently doing drug recovery means that we are exposing patients to molecules that other groups know are destined to fail. That is tragic.” Bountra is very well versed with the nuances of the industry as he has worked for almost 20 years at GSK. He believes that it is not possible for a single company to alone grasp the multitude factors (genetic and others) behind complex and fatal diseases like cancer.


Editor :   Health Filed under Research.

Health Tags: ,

Enter your email address:

Delivered by FeedBurner